Next-generation, selective kinase medicines

Our proprietary scientific platform enables us to rapidly and reproducibly design medicines that selectively target kinase drivers of disease, enabling improved potency, less off-target activity and an increased probability of clinical success.

Discovered by Blueprint Medicines, pralsetinib is an investigational RET inhibitor for advanced thyroid cancer and other RET-altered solid tumors.

Cometriq® (cabozantinib), an FDA-approved multi-kinase inhibitor for advanced medullary thyroid cancer (MTC)

Caprelsa® (vandetanib), an FDA-approved multi-kinase inhibitor for advanced MTC

Kinome illustrations reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

A focused strategy

Our research focuses on kinase targets where we believe our technology can lead to meaningful improvements in treatment.

Difficult-to-drug

Well-recognized kinases that are difficult to target with existing technologies

Treatment-resistant

Mutant kinases that have become resistant to current treatments

Novel biology

New targets identified with our computational and cell biology expertise